IRRAS (DB:4Z7) - Stock Price, News & Analysis

4Z7 Stock Overview

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. More details

4Z7 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 84.69% per year

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Does not have meaningful revenue (SEK43M)

Shareholders have been diluted in the past year

+ 1 more risk

IRRAS AB (publ) Competitors

PULSION Medical Systems

MUN:PUS

€134.4m

Stratec

XTRA:SBS

€334.9m

Eckert & Ziegler

XTRA:EUZ

€897.2m

Drägerwerk KGaA

XTRA:DRW3

€792.0m

Price History & Performance

Summary of all time highs, changes and price drops for IRRAS
Historical stock prices
Current Share Price	US$0.013
52 Week High	US$0.041
52 Week Low	US$0.01
Beta	0
11 Month Change	0%
3 Month Change	3.15%
1 Year Change	-66.41%
33 Year Change	-98.10%
5 Year Change	n/a
Change since IPO	-97.88%

Recent updates

Shareholder Returns

	4Z7	DE Medical Equipment	DE Market
7D	0%	2.9%	0.8%
1Y	-66.4%	-4.7%	8.6%

Return vs Industry: 4Z7 underperformed the German Medical Equipment industry which returned -0% over the past year.

Return vs Market: 4Z7 underperformed the German Market which returned 0.4% over the past year.

Price Volatility

Is 4Z7's price volatile compared to industry and market?
4Z7 volatility
4Z7 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4Z7 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 4Z7's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	47	Will Martin	www.irras.com

IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. The company designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. It offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma.

IRRAS AB (publ) Fundamentals Summary

How do IRRAS's earnings and revenue compare to its market cap?
4Z7 fundamental statistics
Market cap	€167.97m
Earnings (TTM)	-€196.40m
Revenue (TTM)	€43.10m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is 4Z7 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4Z7 income statement (TTM)
Revenue	SEK 43.10m
Cost of Revenue	SEK 44.03m
Gross Profit	-SEK 935.00k
Other Expenses	SEK 195.47m
Earnings	-SEK 196.40m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Feb 21, 2024

Earnings per share (EPS)	-0.17
Gross Margin	-2.17%
Net Profit Margin	-455.71%
Debt/Equity Ratio	0%

How did 4Z7 perform over the long term?

See historical performance and comparison

4Z7 Stock Overview

Rewards

Risk Analysis

IRRAS AB (publ) Competitors

MUN:PUS

€134.4m

XTRA:SBS

€334.9m

XTRA:EUZ

€897.2m

XTRA:DRW3

€792.0m

Price History & Performance

Recent News & Updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

Insufficient new directors

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Insufficient new directors

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Insufficient new directors

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

New 90-day low: €0.62

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Revenue misses expectations

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: €0.81

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Revenue misses expectations

Third quarter 2020 earnings released: kr0.47 loss per share

New 90-day high: €0.66

First half earnings released

Shareholder Returns

Price Volatility

About the Company

IRRAS AB (publ) Fundamentals Summary

0.0x

0.0x

Earnings & Revenue